Deferring Elective Urologic Surgery During the COVID-19 Pandemic: The Patients’ Perspective - 31/12/20
, Riccardo Tellini 1, Antonio Andrea Grosso 1, Daniele Amparore 3, Andrea Mari 1, 2, Lorenzo Viola 1, Andrea Cocci 1, Paolo Polverino 1, Enrico Checcucci 3, Paolo Alessio 3, Cristian Fiori 3, Andrea Minervini 1, 2, Marco Carini 1, 2, Francesco Porpiglia 3, Sergio Serni 1, 2Riassunto |
OBJECTIVES |
To explore the perspective of urological patients on the possibility to defer elective surgery due to the fear of contracting COVID-19.
METHODS |
All patients scheduled for elective urological procedures for malignant or benign diseases at 2 high-volume centers were administered a questionnaire, through structured telephone interviews, between April 24 and 27, 2020. The questionnaire included 3 questions: (1) In light of the COVID-19 pandemic, would you defer the planned surgical intervention? (2) If yes, when would you be willing to undergo surgery? (3) What do you consider potentially more harmful for your health: the risk of contracting COVID-19 during hospitalization or the potential consequences of delaying surgical treatment?
RESULTS |
Overall, 332 patients were included (51.5% and 48.5% in the oncology and benign groups, respectively). Of these, 47.9% patients would have deferred the planned intervention (33.3% vs 63.4%; P < .001), while the proportion of patients who would have preferred to delay surgery for more than 6 months was comparable between the groups (87% vs 80%). These answers were influenced by patient age and American Society of Anesthesiologists score (in the Oncology group) and by the underlying urological condition (in the benign group). Finally, 182 (54.8%) patients considered the risk of COVID-19 potentially more harmful than the risk of delaying surgery (37% vs 73%; P < .001). This answer was driven by patient age and the underlying disease in both groups.
CONCLUSIONS |
Our findings reinforce the importance of shared decision-making before urological surgery, leveraging patients’ values and expectations to refine the paradigm of evidence-based medicine during the COVID-19 pandemic and beyond.
Il testo completo di questo articolo è disponibile in PDF.Mappa
| Conflict of Interest: None to report. |
|
| Financial Disclosure: The authors declare that they have no relevant financial interests. |
Vol 147
P. 21-26 - gennaio 2021 Ritorno al numeroBenvenuto su EM|consulte, il riferimento dei professionisti della salute.
